DIO Corporation (KOSDAQ:039840)
16,300
-100 (-0.61%)
Apr 10, 2026, 3:30 PM KST
DIO Corporation Revenue
In the year 2025, DIO Corporation had annual revenue of 164.08B KRW with 37.13% growth. DIO Corporation had revenue of 46.72B in the quarter ending December 31, 2025, with 23.61% growth.
Revenue
164.08B
Revenue Growth
+37.13%
P/S Ratio
1.33
Revenue / Employee
342.54M
Employees
479
Market Cap
218.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 164.08B | 44.43B | 37.13% |
| Dec 31, 2024 | 119.65B | -36.17B | -23.21% |
| Dec 31, 2023 | 155.82B | 24.51B | 18.67% |
| Dec 31, 2022 | 131.31B | -18.73B | -12.48% |
| Dec 31, 2021 | 150.04B | 29.98B | 24.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Samsung Epis Holdings | 3.02T |
| Chong Kun Dang Holdings | 959.01B |
| Daewon Pharmaceutical | 605.43B |
| Samjin Pharmaceuticals | 274.03B |
| Ilyang Pharmaceutical Co.,Ltd | 272.42B |
| Vieworks | 239.33B |